These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 35864224

  • 1. Aggressive immunotherapy combined with bortezomib and rituximab for membranous nephropathy associated with enzyme replacement therapy in Pompe disease.
    Sasaki K, Uchimura T, Inaba A, Otani M, Hanakawa J, Ito S.
    Pediatr Nephrol; 2023 Mar; 38(3):921-925. PubMed ID: 35864224
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease.
    van Kooten HA, Ditters IAM, Hoogeveen-Westerveld M, Jacobs EH, van den Hout JMP, van Doorn PA, Pijnappel WWMP, van der Ploeg AT, van der Beek NAME.
    Orphanet J Rare Dis; 2022 Feb 02; 17(1):31. PubMed ID: 35109913
    [Abstract] [Full Text] [Related]

  • 6. Enzyme replacement therapy and immunotherapy lead to significant functional improvement in two children with Pompe disease: a case report.
    Castellar-Leones SM, Ortiz-Corredor F, Manrique-Hernández D, Sánchez-Peñarete D, Ruiz-Ospina E, Soto-Peña D, Correa-Arrieta C.
    J Med Case Rep; 2024 Jul 18; 18(1):328. PubMed ID: 39020349
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort.
    Desai AK, Baloh CH, Sleasman JW, Rosenberg AS, Kishnani PS.
    Front Immunol; 2020 Jul 18; 11():1727. PubMed ID: 32849613
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.
    Messinger YH, Mendelsohn NJ, Rhead W, Dimmock D, Hershkovitz E, Champion M, Jones SA, Olson R, White A, Wells C, Bali D, Case LE, Young SP, Rosenberg AS, Kishnani PS.
    Genet Med; 2012 Jan 18; 14(1):135-42. PubMed ID: 22237443
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-Term Experience with Anaphylaxis and Desensitization to Alglucosidase Alfa in Pompe Disease.
    Ertoy Karagol HI, Inci A, Terece SP, Kilic A, Demir F, Yapar D, Koken G, Okur I, Ezgu FS, Tumer L, Bakirtas A, Gazi University Enzyme Replacement Therapy Hypersensitivity Study Group.
    Int Arch Allergy Immunol; 2023 Jan 18; 184(4):370-375. PubMed ID: 36623499
    [Abstract] [Full Text] [Related]

  • 13. A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.
    Han SO, Pope R, Li S, Kishnani PS, Steet R, Koeberl DD.
    Mol Genet Metab; 2016 Feb 18; 117(2):114-9. PubMed ID: 26454691
    [Abstract] [Full Text] [Related]

  • 14. Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Study Group.
    Filosto M, Cotti Piccinelli S, Ravaglia S, Servidei S, Moggio M, Musumeci O, Donati MA, Pegoraro E, Di Muzio A, Maggi L, Tonin P, Marrosu G, Sancricca C, Lerario A, Sacchini M, Semplicini C, Bozzoni V, Telese R, Bonanno S, Piras R, Maioli MA, Ricci G, Vercelli L, Galvagni A, Gallo Cassarino S, Caria F, Mongini T, Siciliano G, Padovani A, Toscano A.
    Adv Ther; 2019 May 18; 36(5):1177-1189. PubMed ID: 30879255
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient.
    Rairikar M, Kazi ZB, Desai A, Walters C, Rosenberg A, Kishnani PS.
    Mol Genet Metab; 2017 Sep 18; 122(1-2):76-79. PubMed ID: 28648664
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease.
    Khanna R, Flanagan JJ, Feng J, Soska R, Frascella M, Pellegrino LJ, Lun Y, Guillen D, Lockhart DJ, Valenzano KJ.
    PLoS One; 2012 Sep 18; 7(7):e40776. PubMed ID: 22815812
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.